Evaluation of an IFN-gamma Assay in the Diagnosis of Latent Tuberculosis in Patients with Psoriasis in a Highly Endemic Setting
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
ACTA DERMATO-VENEREOLOGICA
Autores
LIMA, Emerson de Andrade
LIMA, Mariana de Andrade
LORENA, Virginia M. Barros de
GOMES, Yara de Miranda
LUPI, Omar
Citação
ACTA DERMATO-VENEREOLOGICA, v.91, n.6, p.694-697, 2011
Resumo
Screening for latent tuberculosis infection is mandatory before starting anti-tumour necrosis factor treatments, but its diagnosis still poses a challenge. While studies performed in developed countries have demonstrated superior performance of T-cell based interferon-gamma release assay (IGRA) compared with the tuberculin skin test, there is a debate about whether this holds true in tuberculosis endemic areas. The performance of an IGRA kit (T-SPOT.TB) was evaluated in 33 moderate-to-severe untreated psoriasis patients and, as controls, 30 patients with common dermatological diseases at a tuberculosis highly endemic setting. The frequency of positive tuberculin skin test responses and induration size in controls were higher than in psoriasis patients (53% vs. 18% and 9.3 +/- 1.4 vs. 2.6 +/- 0.7 mm, respectively, p<0.001). In contrast, the frequency of positive response and mean number of spots elicited with the T-SPOT.TB test were not significantly different between patients and controls (47% vs. 43% and 14.7 +/- 3.2 vs. 20.5 +/- 3.1 spots/well, respectively). The two tests presented good agreement in the control, but not the psoriasis group (kappa values of 0.625 and 0.375, respectively). Thus, in a highly tuberculosis-endemic setting the T-SPOT.TB test was superior to the tuberculin skin test in diagnosing latent tuberculosis infection in psoriasis, probably because the immune dysregulation of psoriasis shows a lower interference in the in vitro test.
Palavras-chave
psoriasis, TNF, tuberculin skin test, latent tuberculosis infection, interferon-gamma release assay, ELISPOT
Referências
- ALORAINEY IO, 2009, ANN THORAC MED, V1, P5
- Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
- Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756
- Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746
- de Leon DP, 2008, J RHEUMATOL, V35, P776
- Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
- Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
- Lalvani A, 2003, THORAX, V58, P916, DOI 10.1136/thorax.58.11.916
- Lin J, 2008, CLIN IMMUNOL, V126, P13, DOI 10.1016/j.clim.2007.08.012
- Tsiouri G, 2009, DERMATOLOGY, V219, P119, DOI 10.1159/000222431
- Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
- Marques CDL, 2009, RHEUMATOL INT, V30, P57, DOI 10.1007/s00296-009-0910-y
- Laffitte E, 2009, BRIT J DERMATOL, V161, P797, DOI 10.1111/j.1365-2133.2009.09331.x
- Mahomed H, 2006, INT J TUBERC LUNG D, V10, P310
- Pai M, 2006, INT J TUBERC LUNG D, V10, P942
- de Leon DP, 2005, ANN RHEUM DIS, V64, P1360, DOI 10.1136/ard.2004.029041
- Dogan B, 1997, INT J DERMATOL, V36, P263, DOI 10.1046/j.1365-4362.1997.00164.x
- Hill PC, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000068
- Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
- KAPP A, 1988, J INVEST DERMATOL, V90, P511, DOI 10.1111/1523-1747.ep12461005
- KRUEGER GG, 1978, J INVEST DERMATOL, V71, P189, DOI 10.1111/1523-1747.ep12547129
- LINDHOLM L, 1978, ARCH DERMATOL RES, V263, P121, DOI 10.1007/BF00446432
- Mow WS, 2004, CLIN GASTROENTEROL H, V2, P309, DOI 10.1053/S1542-3565(04)00060-6
- MURAKAMI S, 2009, TUBERCULOSIS, V89, P139
- Sellam J, 2007, ANN RHEUM DIS, V66, P1610, DOI 10.1136/ard.2007.069799
- Sichletidis L, 2006, INT J TUBERC LUNG D, V10, P1127
- Silva LCR, 2010, ARCH DERMATOL RES, V302, P255, DOI 10.1007/s00403-009-0982-2
- Sociedade Brasileira de Pneumologia e Tisiologia, 2009, J BRAS PNEUMOL, V35, P1018
- SOUZA TNL, 1999, THESIS MED SCH U SAO